Efficacy and safety of DPP-4 inhibitors in patients with chronic kidney disease

Efficacy and safety of DPP-4 inhibitors in patients with chronic kidney disease - DPP-4 inhibitors in CKD

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009493

Enrollment

Registered

2012-12-07

Start date

2011-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

DPP-4 inhibitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: hemoglobin A1c (HbA1c) level exceeding 7.0% and/or a glycated albumin (GA) level exceeding 21.0% after 8 consecutive weeks of daily administration of conventional therapy (dietary therapy alone or other antidiabetic agents). Type 2 diabetes mellitus eGFR < 60 mL/min/1.73m2

Exclusion criteria

Exclusion criteria: Exclusion criteria are the presence of infectious disease, thyroid disease, malignant tumors and treatment with steroids.

Design outcomes

Primary

Measure	Time frame
Glycemic control	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026